Baseline serum PSA value performed with a Food and Drug Administration (FDA)-approved assay (e.g., Abbott, Hybritech) within 120 days prior to registration
Patients who are receiving any other chemotherapy or investigational agents; radiation treatment will not be permitted during study treatment; patients can receive radiation therapy (XRT) 4 weeks prior to study drug administration or 4 weeks post study completion or discontinuation; steroids equivalent to prednisone 60 mg daily are permitted prior to study drug administration, but needs to be discontinued 1 day prior to BV administration; patients receiving steroids for lymphoma symptoms should have measurable disease as mentioned above on baseline scans
Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug
Female subjects who are lactating must discontinue nursing prior to the first dose of study drug and refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
ELIGIBILITY CRITERIA - PHASE II (ARM D): Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent\r\n* Patients with WBC count above 20 x10^9/L may be eligible if they start steroids or hydroxyurea per institutional guidelines, but they must discontinue before day 1 of study drug
Any chemotherapy within the 28 days prior to the first dose of study drug.
Patient has had chemotherapy within 28 days prior to first administration of study drug.
Immunomodulating agents <28 days prior to first dose of study drug
Steroid treatment within seven (7) days prior to study treatment. Patients that require intermittent use of bronchodilators, topical steroids or local steroid injections will not be excluded from the study. Patients who have been stabilized to 10 mg PO QD or less seven (7) days prior to study drug administration are allowed.
No previous treatment with the specific assigned study drug or any other drug sharing the same target; prior treatment in monotherapy when treated in one of the combination arms in the study is allowed
Prior definitive radiation therapy must have been completed at least 6 weeks before study drug administration and the irradiated lesions should show evidence of progression if they are intended to be considered target lesions. Prior palliative radiotherapy must be completed at least 2 weeks before study drug administration. The radiotherapy-related side effects must have resolved before the study entry. No radiopharmaceuticals (strontium, samarium) will be allowed within 8 weeks before study drug administration.
Chemotherapy, radioactive, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or not recovered from clinically significant adverse events due to cancer therapeutics administered more than 4 weeks prior to the first dose of study drug
Treatment with antibiotics within 14 days prior to first dose of study drug.
Is pregnant or breast feeding or expecting to conceive or father starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication
Participant has had prior antineoplastic therapy within 14 days prior to starting study drug.
Participant that received in the 7 days prior to the administration of study drug or is currently receiving any of the following medications:
No previous treatment with the specific assigned study drug or any other drug sharing the same target
History of any of the following within the last 6 months before administration of the first dose of the study drugs:
Has had any major cardiovascular event within 6 months prior to study drug administration
Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before the start of study therapy.
Neurological stability for at least 14 days prior to first dose of study drug;
Significant mental illness in the 4-week period preceding drug administration.
Patients must not have received any vaccines for 28 days prior to administration of their first dose of MT-3724 and should not receive any vaccine during the study or within 28 days after their last dose of MT-3724.
Last dose with any of the following agents including but not limited to: etanercept, infliximab, tacrolimus, cyclosporine, mycophenolic acid, alefacept, or efalizumab <28 days prior to first dose of study drug
Female subjects who are breastfeeding, or intend to breastfeed during the duration of the study and for 30 days following the last dose of study drug.
Breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Treatment with therapeutic doses of metaiodobenzylguanidine (MIBG) ?6 weeks before first dose of study drug
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug administration until 90 days after the last dose of study drug.
Non-sterile male subjects must use contraceptive methods with partner(s) prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug; male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug
Participants may not concomitantly use statins while on study; however, a patient using statins for over 3 months prior to study drug administration and in stable status without CK rise may be permitted to enroll
Patients who have had chemotherapy within 2 weeks prior to first dose of study drug.
CLL therapy, with the exception of ibrutinib within the following timeframes:\r\n* Chemotherapy, external beam radiation therapy, anticancer antibodies within 30 days prior to the first dose of drug on this study\r\n* Corticosteroid use >= 20mg prednisone within 1 week prior to first dose on this study\r\n* Radio- or toxin-conjugated antibody therapy within 10 weeks prior to first dose on this study\r\n* Allogeneic stem cell transplant within 6 months prior to first dose on this study
Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpetation of study results.
Received hydroxyurea therapy within 28 days (4 weeks) before the first dose of any study drug
Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:
At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
There are no prohibitions of specific medications on the basis of anticipated drug-drug interactions
Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drug, except for hydroxyurea
Breastfeeding should be discontinued until 6 weeks after the last administration of study drug
Surgery within 4 weeks of study drug administration
History of any of the following within the last 3 months before administration of the first dose of study drug:
Subject has no significant worsening in clinical status for a minimum of 7 days prior to first dose of study drug.
At least 84 days must have elapsed after stem cell infusion prior to study drug administration
Phase 1: Received prior therapy with eribulin mesilate within 6 months prior to study drug administration.
Laparoscopic procedure or open biopsy within 7 days prior to study drug administration
The following restrictions apply to current or prior anti-cancer treatment, prior to the first dose of study drug:\r\n* Patients who are actively receiving any other investigational agents\r\n* Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks prior to the first dose of study drug\r\n* Radio- or toxin-immunoconjugates within 10 weeks prior to the first dose of study drug\r\n* Previous treatment with greater than one of the study agents (i.e., venetoclax, ibrutinib, obinutuzumab or Revlimid), excluding prior prednisone or rituximab treatment\r\n* Prior allogeneic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug\r\n* Not recovered (i.e., =< grade 1 or baseline) from adverse events due to previously administered anti-cancer treatment, surgery, or procedure; NOTE: exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)
Within 14 days of the first dose of study drug: Platelets >= 100,000/·L
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 90 days after the last dose of study drug
Serum creatinine =< 1.5 x ULN (results within 7 days before study drug administration)
To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug. If the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug.
Anti-cancer therapy less than 14 days prior to the first dose of study drug (less than 28 days for bevacizumab) or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug
Anti-cancer therapy less than 6 weeks prior to the first dose of study drug (less than 28 days for bevacizumab) or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug
Patients scheduled for definitive cancer surgical resection less than 7 days from beginning of study drug administration or greater than 6 weeks from beginning of study drug administration
At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
Anti-cancer therapy less than 14 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug
Patients who have received systemic nonsteroidal antiinflammatory drug (NSAID) therapy within 14 days prior to the first dose of study drug
Patients being treated with medications with drug-drug interactions with study agents will require evaluation by to determine if full doses of all study treatments can be given safely; significant drug-drug interactions will need to be addressed prior to enrollment; alternatively, the patient will not be eligible
Patients receiving anti-retroviral therapy or other agents that are contra-indicated with nelfinavir due to drug-drug interactions
Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug. Following major surgeries, >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.
History of any of the following within the last 6 months before administration of the first dose of study drug:
Patients scheduled for definitive cancer surgical resection less than 7 days from beginning of study drug administration or greater than 5 weeks from beginning study drug administration
Treatment with any of the following within the specified time frame prior to the study drug administration:
Prior major surgery must be completed at least 4 weeks before study drug administration; prior minor surgery must be completed at least 1 week before study drug administration and subjects should be recovered; percutaneous biopsies should be completed at least 10 days prior to study drug administration
ENTRECTINIB EXCLUSION CRITERIA: Pulmonary embolism in the 3 months prior to study drug administration
Within 14 days of first dose of study drug administration: Platelets >= 100,000/mcl
Pharmacologic therapy with agents reported to produce adverse drug-drug interactions. (Table 2)
Administration of agents with potential QT interval prolonging effects within 14 days prior to the first administration of study drug and while on treatment
Participants who have received any of the following prior to the first dose of study drug:
Radiation therapy within four weeks prior to administration of the first dose of study drug • To be eligible for study treatment, radiation therapy-related toxicity must recover to Grade ? 1 prior to administration of the first dose of study drug. Concurrent palliative radiotherapy for local pain-control may be allowed, provided the subject does not meet criteria of progressive disease and treated lesions will not be included in the target/non-target lesion assessment.
Any of the following within 6 months prior to study drug administration:
Baseline serum PSA value performed with an Food and Drug Administration (FDA)-approved assay (e.g., Abbott, Hybritech) within 12 weeks (90 days) prior to registration
Less than or equal to (</=) 96 hours between onset of ILI and first dose of study drug
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Received radiotherapy ?14 days prior to the first dose of AP32788 of study drug.
Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with brain lesions clinically indicated for surgical resection as well as consent to provide tissue for drug concentration determination after 5 to 14 days of study drug dosing.
Baseline serum PSA value performed with a Food and Drug Administration (FDA)-approved assay (e.g., Abbott, Hybritech) within 60 days prior to registration
Laparoscopic procedure or open biopsy within 7 days prior to study drug administration
Received study contraindicated medications prior to study drug administration including but not limited to those listed in the Full Prescribing Information Sheet for ledipasvir/sofosbuvir (Harvoni®).
Subjects of childbearing potential must consent to utilize a medically accepted means of contraception throughout the active dosing period with study medication and for a minimum of 30 days following the administration of the last dose of study medication.
Must be willing to implement contraception throughout study and for 120 days after receiving the study drug.
Medical history of RBC transfusion dependent anemia ?4 units of RBCs during the 16 weeks prior to admin of study drug & ?2 units of RBCs over prior 8 weeks (day -56 to day 1 prior to treatment; baseline period) for documented Hgb of ? 9g/dL (during baseline). Didn't have a 56 day RBC transfusion-free period during 16 weeks prior to administration of study drug.
Within 14 days of first dose of study drug: Platelets > 100 x 10^9/L
Appropriate for single agent study drug therapy as prescribed by this protocol;
Patient has any of the following within 14 days prior to the first dose of study drug:
TREATMENT: Breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drug
Must be willing to implement contraception throughout study and for the 4 weeks following last viral administration
Had involvement in the planning and/or conduct of the study by association with the sponsor, study drug supplier(s) or study center or was previously enrolled in the present study
Non-study related surgical procedures less than or equal to 7 days prior to\n             administration of rociletinib. In all cases, the patient must be sufficiently\n             recovered and stable before treatment administration
Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before first dose of study drug
Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration; prior focal radiotherapy completed at least 2 weeks before study drug administration; no radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration
Completed nitrosourea treatment at least 6 weeks before administration of any study drug
Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration\r\n* Prior focal radiotherapy completed at least 2 weeks before study drug administration\r\n* No radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration
Completed nitrosourea treatment at least 6 weeks before administration of any study drug
Patient is currently participating or has participated in a study with an investigational compound or devise within 30 days of initial dosing with study drug(s)
Subject is suitable for oral administration of study drug.
Immunostimulants within 4 weeks or immunosuppressants within 14 days prior to study drug
Anti-cancer therapy less than 28 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug.
Last dose of any prior therapy administered by the following time intervals before the first dose of study drug:
Completion of, if applicable, radiotherapy, chemotherapy, antibodies and immunoconjugates including brentuximab vedotin and/or another investigational drug which could interact with this trial not less than 4 weeks (or 5 half-lives of the drug, whichever occurs later) prior to first dose of study drug. Cessation of small molecule tyrosine kinase inhibitors must be at least 7 days prior to first dose of study drug.
Male patients must use a condom from the time of the first administration of ONO-7475 until 4 months following administration of the last dose.
Time required between the last dose of the latest therapy and the first dose of study drug:
Subject must currently be participating in an Astellas sponsored, single agent ASP2215 trial, receiving ASP2215 and have not met any discontinuation criteria of the parent study and can enroll into this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.
Pleurodesis within 14 days prior to first dose of study drug
Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration; prior focal radiotherapy completed at least 2 weeks before study drug administration; no radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administration
Completed nitrosourea treatment at least 6 weeks before administration of any study drug
History of any of the following within the last 6 months before administration of the first dose of study drug
Breastfeeding should be discontinued until 6 weeks after the last administration of study drug
Surgery within 4 weeks of study drug administration
Use of any investigational, non-United States Food and Drug Administration (US FDA) approved drug
Patients who have received any investigational agent, chemotherapy, interferon-alpha, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1; or monoclonal antibody =< 6 weeks prior to first administration of study treatment (patients with an AHNMD with progressive leukocytosis who require control of their counts are permitted to be given hydroxyurea); EXCEPTION: midostaurin can be used up to 10 days before the start of the study drug (study day 1)
Received prior systemic cytotoxic chemotherapy, biological therapy, major surgery within 3 weeks of first dose of study drug; received thoracic radiation therapy of > 30 gray (Gy) within 6 months of first dose of study drug
Currently receiving or has received any intensive chemotherapy within the 14 days prior to the first dose of study drug (day -7) (Hydrea or other non-intensive regimens such as decitabine may be used but must stop at least one day prior to the first dose of study drug)
Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug:
Prior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of >30 Gy within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drug
Subject is suitable for oral administration of study drug.
Treatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration
Received any subsequent anti-cancer therapies from the time between the last dose of atezolizumab prior to the first administration of study drug after crossing over
Whole brain radiation within 28 days or other radiotherapy within 14 days prior to first administration of study drug after crossing over
Treatment with non-Food and Drug Administration (FDA) approved drug within 21 days of start of this trial
Treatment with a non-Food and Drug Administration (FDA) approved drug in the previous 4 weeks
Any non-study related significant surgical procedures within the past 28 days prior to the first administration of study drug
Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 180 days after the last dose of study drug.
Patient who has had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study drug
Radiotherapy within 14 days before the first dose of study drug.
Radioimmunotherapy within 4 weeks before first dose of study drug
FOCBP must have a negative pregnancy test within 7 days prior to registration on study\r\n* Note: female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Subject is suitable for oral administration of study drug.
Patient who has had chemotherapy, or biological cancer therapy within 2 weeks prior to the first dose of study drug; patient who has had radiation within 2 weeks prior to the first dose of study drug
Female subjects of child-bearing potential must agree to undergo medically supervised pregnancy test prior to starting study drug. The first pregnancy test will be performed at screening (within 7 days prior to first study drug administration), and on the day of the first study drug administration and confirmed negative prior to dosing and Day 1 before dosing all subsequent cycles.
Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment; immunotherapy, radiotherapy or experimental therapy within 28 days of first day of study drug dosing, or within six weeks of first day of study drug dosing in the event that nitrosoureas or mitomycin were used; concurrent systemic immunosuppressant therapy other than corticosteroids (e.g. cyclosporine A, tacrolimus, etc) must be discontinued within 28 days of the first dose of study drug
Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of 28 days prior to registration from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:\r\n* 14 days from administration of vincristine\r\n* 42 days from administration of nitrosoureas\r\n* 21 days from administration of procarbazine
discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.
At the time of trial enrollment, participants may be receiving one or two other immunosuppressive therapies in addition to glucocorticoids; immunosuppressant doses must be stable for 14 days prior to starting study drug; monoclonal T or B cell antibodies must be discontinued at least 28 days before starting study drug
Have taken certain medications or had grapefruit juice within 7 days of initial dose of study drug, as levels of the study drug may be affected.
A woman who is pregnant or breast feeding, or a man who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Any prior therapy for castrate disease is acceptable except prior abiraterone, which is excluded; a minimum washout of 28 days for any other anticancer therapy prior to first dose of study drug is required\r\n* Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug\r\n* Denosumab or zoledronic acid are allowed
Ability to receive study drug therapy by enteral administration
Plan to father a child while enrolled in this study or within 90 days after the last dose of study drug.
For women of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to 90 days following the last study drug administration
Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy. • Agree not to share study medication with another person.
Subject has received intervening anticancer treatment or previous treatment with chemotherapy for metastatic disease other than palliative local radiation to painful bone metastases completed at least 1 week prior to the first dose of study drug. The administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has finalized ? 6 months before the first dose of study drug.
Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration.
Use of drugs that might pose a risk of a drug-drug interaction within 4-7 days before the start of study therapy.
Agree not to share either study drug with another person.
Non-study related surgical procedures less than or equal to 7 days prior to administration of study drug. In all cases, the patient must be sufficiently recovered and stable before treatment administration.
Subject has any of the following within 14 days prior to the first dose of study drug:
Subject has received the following within 14 days prior to the first dose of study drug:
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 28 days prior to the first administration of study drug and agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administration
Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from 30 days prior to the first study drug administration to 90 days following the last study drug administration
Received any of the following within the specified time frame prior to the first administration of study drug:
Subject has history of gastrointestinal ulcer within 28 days prior to the first dose of study drug.
Prior cancer therapy or other investigational therapy within 2 weeks before the first administration of study drug or failed to recover from the reversible effects of prior anticancer therapies. For prior therapies with a half-life longer than 3 days, the interval must be at least 28 days before the first administration of study drug, and the participant must have documented progressive disease.
Has taken histamine-H2 receptor antagonists and/or neutralizing antacids within 24 hours before the first administration of study drug.
Poor venous access for study drug administration; in this case, patients would require a peripheral or central indwelling catheter for study drug administration; study drug administration via indwelling catheters is prohibited at this time unless silicone based catheters are used; anything other than catheters made from silicone are not allowed with ganetespib therapy
Therapy with samarium-153, strontium-89, or radium-223 within 8 weeks prior to first dose of study drug.
Participated in another drug study within 90 days before this one
Currently enrolled in (or completed within 30 days before study drug administration)another investigational drug study.
Currently enrolled in (or completed) another investigational drug study within 30 days prior to study drug administration
Antineoplastic therapy, radiotherapy, or any other investigational drug within 30 days prior to first study drug administration
Unable to return at the regular required intervals for reassessment, or study drug administration
Previous radiotherapy (unless brachytherapy), endocrine therapy, chemotherapy, or exposure to investigational medicinal products during the 4 weeks (6 weeks for nitrosoureas and Mitomycin-C) or 4 drug half-lives before the planned administration of the first dose of study drug, whichever is greater. Previous immunotherapy during the 4 weeks before the planned administration of the first dose of study drug.
Male subjects with pregnant or lactating partners or partners who plan to become pregnant while on study or within 6 months after the planned administration of the last dose of study drug
Systemic investigational drug of any kind within 6 weeks of AVB-620 administration
Patient has an infection and has had a body temperature of > 38.3?C within 48 hours prior to planned first dose of study drug.
surgery, radiation, or immunosuppressants within 28 days prior to planned first dose of study drug,
mitomycin-C or nitrosoureas within 42 days prior to planned first dose of study drug. Note: Patients receiving LHRH agonists or antagonists or antiestrogens or aromatase inhibitors started and at a stable dose for at least 90 days prior to planned first dose of study drug are eligible. Patients are permitted one 28 day cycle of concurrent treatment with hydroxyurea during the study.
Required screening laboratory data (within 2 weeks prior to administration of study drug) as shown in study protocol.
Subject has had any of the following within 14 days prior to the first dose of study drug:
Radiotherapy within 14 days before the first dose of study drug.
Any of the following clinical laboratory results during screening (i.e., within 28 days before the first dose of either study drug):
Poor venous access for study drug administration\r\n* Study drug administration via indwelling catheters is allowed only if the catheter is made of silicone material
Planned treatment with NovoTTF therapy alone per Food and Drug Administration (FDA)-approved indication; NovoTTF therapy must start within 14 days of registration, but not less than 7 days or more than 21 days from stereotactic biopsy (if applicable) and not less than 21 days or more than 42 days from open resection (if applicable)
High-dose chemotherapy within 4 weeks of study drug
Antileukemia treatment within 14 days of study drug (other than hydroxyurea or 6-mercaptopurine)
hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration;
Subject has received aspirin or warfarin within 7 days prior to the first dose of study drug
Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of study drug, except for hydroxyurea
WCBP must agree to have pregnancy tests monthly (every 14 days for women with irregular cycles) while on study drug and 4 weeks after the last dose of study drug
Vomited in the 24 hours prior study drug administration (Cycle 1)
Treatment with molecularly targeted agents within the past 3 weeks prior to planned first study drug administration. Patients who were receiving standard chemotherapy or experimental therapies must wait 4 weeks from their last dose prior to the planned first study drug administration. Patients treated with nitrosoureas or mitomycin C must wait 6 weeks from their last dose prior to the planned first study drug administration.
Herbal supplements are prohibited 1 week prior to the planned first study drug administration, during the clinical study, and up to the time that the patient is discharged from the study
No concurrent radiotherapy or chemotherapy may be given to the patient during the administration of the study drug
Administration of an investigational study treatment within 30 days preceding the first dose of study treatment(s) in this study.
INTRATUMORAL DRUG DISTRIBUTION STUDY PATIENTS:
Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of: \r\n* 28 days from the administration of any investigational agent\r\n* 28 days from administration of prior cytotoxic therapy with the following exceptions: \r\n** 14 days from administration of vincristine\r\n** 42 days from administration of nitrosoureas\r\n** 21 days from administration of procarbazine\r\n* 7 days from administration of non-cytotoxic agents (e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. [radiosensitizer does not count])\r\n* 28 days from prior radiation therapy
Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study drug or for 180 days after the last dose of study drug.
Participants who have received any of the following within the listed time frame, prior to the first dose of study drug
Participants who have received the following within 7 days prior to the first dose of study drug:
For women of child-bearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration
Therapy with anticoagulant or antithrombotic agents (including aspirin) within 7 days prior to study drug administration
Patients may not be receiving any agents not approved by the Food and Drug Administration (FDA) within the past 4 weeks
Acute MI ? 3 months prior to dosing with study drug
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
The first ASCI administration should be given within one year after the last chemotherapy administration. All screening procedures should be completed within seven weeks before the first ASCI administration.
Agree to abstain from donating blood while taking study drug therapy and following discontinuation of study drug therapy.
Anticoagulant drug therapy,
Subject must be receiving a stable dose of ASP8273 for 14 days minimum and is able to enroll into this rollover study without treatment interruption of study drug, or with no more than 21 consecutive days of treatment interruption in study drug within the parent study.
To avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug; if the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners; donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug
Subject has received a prior EGFR inhibitor within 6 days prior to the first dose of study drug.
Subject has had any of the following within 14 days prior to the first dose of study drug:
Administration of any non-oncologic investigational drug within 30 days prior to receiving the first dose of topotecan/pazopanib
21 days from administration of procarbazine
Treatment with any Food and Drug Administration (FDA) non-approved study medication within the past four weeks; off label treatment with FDA approved medication is allowed
Patient is a woman with a positive urine or serum pregnancy test within 3 days prior to study drug administration, is breast-feeding, or is planning to conceive children within the projected duration of the study treatment
Patient who is participating in any investigational agent that is not Food and Drug Administration (FDA)-approved
Treatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration
The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug
Patient who experienced any vomiting, retching, or nausea within 24 h prior to the administration of the study drug
Patient who received palonosetron within 1 week prior to administration of study drug.
Is pregnant or expecting to conceive, is breastfeeding, or plans to breastfeed from the time of consent through 90 days after the last dose of study drug
Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Prior treatment with Food and Drug Administration (FDA)-approved or investigational biologics or novel molecularly target therapies, including oral or IV formulations, are permitted; patients must be off prior targeted therapy for at least 14 days prior to study biopsy
Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours (h) after their final CEUS exam
HEALTHY VOLUNTEER: Participation in an investigational drug study within the period starting 1 month before study drug administration
Subjects will receive the standard Food and Drug Administration (FDA)-approved dose and schedule of 5-azacytidine; this dose is 75 mg/m^2 SC or intravenously (IV) daily for seven days with cycles repeated every 28 days
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Surgical intervention within 28 days prior to the first dose of M3541 administration
Treatment with systemic chemotherapy or investigational therapy within 4 weeks of first study drug administration; other agents (e.g., biologics) within 2 weeks; radiation within 2 weeks; patients receiving 131I-MIBG therapy must wait 6 weeks prior to the initiation of study drug administration; corticosteroids (? 0.2 mg/kg/day prednisone or equivalent) or other immune suppressive drugs within the 2 weeks prior to the initiation of study drug administration.
Subject is suitable for oral administration of study drug.
Off study use of ketorolac or other NSAIDs prior to study administration within the perioperative window (7 days before surgery and up to the time of planned study administration)
Allergy/sensitivity to any study drug (degarelix, enzalutamide, trametinib, dasatinib), or drugs chemically related to study drug, or excipients or to dimethylsulfoxide
Patients must not be on enzalutamide within five half-lives before the first planned dose of the study drug or anticipating to start enzalutamide within the next 3 months of the first planned dose of study drug
CLL therapy, with the exception of ibrutinib within the following timeframes:\r\n* Chemotherapy, external beam radiation therapy, anticancer antibodies within 30 days prior to the first dose of drug on this study\r\n* Corticosteroid use >= 20 mg prednisone within 1 week prior to first dose on this study\r\n* Radio- or toxin-conjugated antibody therapy within 10 weeks prior to first dose on this study\r\n* Allogeneic stem cell transplant within 6 months prior to first dose on this study
